US Stock MarketDetailed Quotes
OMGA Omega Therapeutics
- 0.783
- +0.007+0.86%
Trading Nov 22 13:04 ET
43.34MMarket Cap-592P/E (TTM)
0.793High0.760Low120.12KVolume0.760Open0.776Pre Close93.00KTurnover0.56%Turnover RatioLossP/E (Static)55.37MShares6.30052wk High3.76P/B16.86MFloat Cap0.75052wk Low--Dividend TTM21.54MShs Float31.410Historical High--Div YieldTTM4.28%Amplitude0.750Historical Low0.774Avg Price1Lot Size
Omega Therapeutics Stock Forum
Sign in to post a comment
$Omega Therapeutics (OMGA.US)$
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Ampersand's AND™ Platform will be used to identify programmed biologics for the
treatment of obesity-related targets
Montai's CONECTA™ AI platform will be used to identify small molecules directed to a
potential Non-Small Cell Lung Cancer-related target
Collaborations will leverage Pfizer's deep expertise in early di...
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Ampersand's AND™ Platform will be used to identify programmed biologics for the
treatment of obesity-related targets
Montai's CONECTA™ AI platform will be used to identify small molecules directed to a
potential Non-Small Cell Lung Cancer-related target
Collaborations will leverage Pfizer's deep expertise in early di...
1
$Omega Therapeutics (OMGA.US)$
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Positive
Phase 1 MYCHELANGELO trial showed 50% disease control rate in HCC patients
Reduced net loss to $16.4M in Q3 2024 from $22.2M in Q3 2023
R&D expenses decreased by $3.7M compared to Q3 2023
G&A expenses reduced by $1.0M compared to Q3 2023
Ongoing collaboration with Novo Nor...
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Positive
Phase 1 MYCHELANGELO trial showed 50% disease control rate in HCC patients
Reduced net loss to $16.4M in Q3 2024 from $22.2M in Q3 2023
R&D expenses decreased by $3.7M compared to Q3 2023
G&A expenses reduced by $1.0M compared to Q3 2023
Ongoing collaboration with Novo Nor...
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Omega Therapeutics (OMGA.US)$ interesting
$Omega Therapeutics (OMGA.US)$
Might buy some tomorrow if price goes below $1 again.
Very nice moves.
Might buy some tomorrow if price goes below $1 again.
Very nice moves.
$Omega Therapeutics (OMGA.US)$
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics (Nasdaq: OMGA) has published preclinical data for OTX-2002, their epigenomic controller targeting the MYC gene in hepatocellular carcinoma (HCC), in Nature Communications. The study demonstrates OTX-2002's ability to downregulate MYC expression and inhibit tumor growth in HCC models, both as a monotherapy and in combination wi...
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics (Nasdaq: OMGA) has published preclinical data for OTX-2002, their epigenomic controller targeting the MYC gene in hepatocellular carcinoma (HCC), in Nature Communications. The study demonstrates OTX-2002's ability to downregulate MYC expression and inhibit tumor growth in HCC models, both as a monotherapy and in combination wi...
$Omega Therapeutics (OMGA.US)$
NEWS
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
NEWS
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
1
$Omega Therapeutics (OMGA.US)$ let’s go!
2
RECAP
Investors Rethink Rate Cut Bets
US equities ended Friday slightly higher, but gains weren't enough to keep major indices in the green in the first trading week of the year. The stock market ended their nine-week winning streak as investors rethink bets of aggressive interest rate cuts this year amid signs of continued strength in the labor market.
The $S&P 500 Index (.SPX.US)$ rose 0.2% to close at 4,697.24 Friday, while the $Nasdaq Composite Index (.IXIC.US)$ rose less...
Investors Rethink Rate Cut Bets
US equities ended Friday slightly higher, but gains weren't enough to keep major indices in the green in the first trading week of the year. The stock market ended their nine-week winning streak as investors rethink bets of aggressive interest rate cuts this year amid signs of continued strength in the labor market.
The $S&P 500 Index (.SPX.US)$ rose 0.2% to close at 4,697.24 Friday, while the $Nasdaq Composite Index (.IXIC.US)$ rose less...
38
2
$Omega Therapeutics (OMGA.US)$ tumbled 18%, giving back some of its meteoric gains on Thursday that were driven by optimism over the clinical-stage biotechnology company's research collaboration pact with Novo Nordisk.
Omega shares almost doubled Thursday after the company said its flagship’s Pioneering Medicines initiative, and Novo Nordisk will jointly advance an obesity management program through preclinical development and...
Omega shares almost doubled Thursday after the company said its flagship’s Pioneering Medicines initiative, and Novo Nordisk will jointly advance an obesity management program through preclinical development and...
7
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
104294857 : no trading volume
no one noticed this stock